Motavizumab

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants.[1] As of September 2009, it is undergoing Phase II and III clinical trials.[2]

Motavizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetRSV glycoprotein F
Clinical data
Trade namesNumax
Routes of
administration		Intravenous
ATC code
Pharmacokinetic data
Protein bindingNone
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6476H10014N1706O2008S48
Molar mass145438.16 g·mol−1
 NY (what is this?)  (verify)

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[3]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[4]

References
  1. Kalergis AM, Soto JA, Gálvez NM, Andrade CA, Fernandez A, Bohmwald K, Bueno SM (December 2020). "Pharmacological management of human respiratory syncytial virus infection". Expert Opinion on Pharmacotherapy. 21 (18): 2293–2303. doi:10.1080/14656566.2020.1806821. PMID 32808830.
  2. ClinicalTrials.gov
  3. "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
  4. "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.
  • "Motavizumab". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.